Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial

Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley

doi:10.1200/JCO.2010.31.4310

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial

Alan K Burnett, Robert K Hills, Donald Milligan, Lars Kjeldsen, Jonathan Kell, Nigel H Russell, John A L Yin, Ann Hunter, Anthony H Goldstone, Keith Wheatley

570 Citationer (Scopus)

Abstract

Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients.

Originalsprog	Engelsk
Tidsskrift	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Vol/bind	29
Udgave nummer	4
Sider (fra-til)	369-77
Antal sider	9
DOI	https://doi.org/10.1200/JCO.2010.31.4310
Status	Udgivet - 1 feb. 2011

Adgang til dokumentet

10.1200/JCO.2010.31.4310

Citationsformater

Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011). Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(4), 369-77. https://doi.org/10.1200/JCO.2010.31.4310

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. / Burnett, Alan K; Hills, Robert K; Milligan, Donald et al.
I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Bind 29, Nr. 4, 01.02.2011, s. 369-77.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Burnett, AK, Hills, RK, Milligan, D, Kjeldsen, L, Kell, J, Russell, NH, Yin, JAL, Hunter, A, Goldstone, AH & Wheatley, K 2011, 'Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, bind 29, nr. 4, s. 369-77. https://doi.org/10.1200/JCO.2010.31.4310

@article{116855ea284a4a6c8ebaa280a6066e28,

title = "Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial",

abstract = "Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients.",

author = "Burnett, {Alan K} and Hills, {Robert K} and Donald Milligan and Lars Kjeldsen and Jonathan Kell and Russell, {Nigel H} and Yin, {John A L} and Ann Hunter and Goldstone, {Anthony H} and Keith Wheatley",

year = "2011",

month = feb,

day = "1",

doi = "10.1200/JCO.2010.31.4310",

language = "English",

volume = "29",

pages = "369--77",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial

AU - Burnett, Alan K

AU - Hills, Robert K

AU - Milligan, Donald

AU - Kjeldsen, Lars

AU - Kell, Jonathan

AU - Russell, Nigel H

AU - Yin, John A L

AU - Hunter, Ann

AU - Goldstone, Anthony H

AU - Wheatley, Keith

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients.

AB - Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients.

U2 - 10.1200/JCO.2010.31.4310

DO - 10.1200/JCO.2010.31.4310

M3 - Journal article

C2 - 21172891

VL - 29

SP - 369

EP - 377

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

IS - 4

ER -

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater